Evoq Remedies

What does Evoq Remedies do?

Evoq Remedies Ltd is a Micro Cap company in the Trading & Distributors industry, previously known as Salus Life Science and Research Private Limited. It has no recent sales or profit data, with a market cap of Rs 11 Cr and a P/E ratio of 11.00.

Overview:<BR>Evoq Remedies Ltd operates in the Trading & Distributors industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Evoq Remedies Ltd was originally incorporated as "Salus Life Science and Research Private Limited" in 2010. The company changed its name to "Evoq Remedies Private Limited" on July 15, 2019. There is no sales and profit data available for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: Rs 11 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 11.00<BR>Industry P/E: 35<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.16<BR>Return on Equity: 0.36%<BR>Price-to-Book: 0.42<BR><BR>Contact Details:<BR>Address: Not available<BR>Phone: Not available<BR>Email: Not available<BR>Website: Not available

Has Evoq Remedies declared dividend?

No Dividend History Available

Who are the peers of the Evoq Remedies?

Evoq Remedies' peers include Redington, MMTC, MSTC, Ravindra Energy, Sun Retail, Nouveau Global, and Mystic Electron. In terms of management risk, growth, and capital structure, Redington stands out positively, while Evoq Remedies shows average performance and a 1-year return of -55.22%.

Peers: The peers of Evoq Remedies are Redington, MMTC, MSTC, Ravindra Energy, Sun Retail, Nouveau Global, and Mystic Electron.<BR><BR>Quality Snapshot: Excellent management risk is observed at Redington, while Average management risk is found at MMTC, MSTC, and Evoq Remedies, and the rest. Below Average management risk is noted for Ravindra Energy and Sun Retail. In terms of Growth, Excellent growth is seen at Redington, Average growth at Sun Retail, and Below Average growth at MMTC, MSTC, Evoq Remedies, Ravindra Energy, and the rest. For Capital Structure, Excellent capital structure is present at MSTC, while Good capital structure is noted for Redington, and Below Average capital structure is found at MMTC, Evoq Remedies, Ravindra Energy, Sun Retail, and the rest.<BR><BR>Return Snapshot: Ravindra Energy has the highest 1-year return at 142.31%, while MSTC has the lowest at -39.73%. Evoq Remedies' 1-year return is -55.22%, which is lower than both. Additionally, MSTC, Evoq Remedies, Sun Retail, Nouveau Global, and Mystic Electron have negative six-month returns.

Is Evoq Remedies overvalued or undervalued?

As of April 11, 2025, Evoq Remedies is rated as "risky" and overvalued, with a PE ratio of 10.63, negative EV to EBITDA of -6.61, and a Price to Book Value of 0.42, significantly underperforming against peers and the Sensex.

As of 11 April 2025, Evoq Remedies has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios include a PE ratio of 10.63, an EV to EBITDA of -6.61, and a Price to Book Value of 0.42, which indicate significant concerns regarding profitability and valuation relative to its assets.<BR><BR>In comparison to peers, Evoq Remedies' PE ratio is substantially lower than that of Sun Pharmaceutical Industries Ltd. at 35.25 and Divi's Laboratories Ltd. at 79.33, both of which are categorized as expensive. Additionally, the company's negative EV to EBIT and EV to EBITDA ratios suggest that it is not generating positive earnings, further emphasizing its overvaluation status. Notably, Evoq Remedies has underperformed significantly against the Sensex over the past year, with a stock return of -52.41% compared to the Sensex's 7.55%, reinforcing the notion of its current overvaluation.

What is the technical trend for Evoq Remedies?

As of June 3, 2025, Evoq Remedies shows a neutral technical trend with mixed signals: weekly indicators are mildly bullish while monthly indicators are mildly bearish, reflecting a weak overall trend.

As of 3 June 2025, the technical trend for Evoq Remedies has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating divergence. The weekly RSI is bullish, but the monthly RSI shows no signal, suggesting a lack of momentum in the longer term. Bollinger Bands are bullish on the weekly chart but mildly bearish on the monthly, further reflecting the mixed outlook. Daily moving averages are mildly bearish, which contrasts with the weekly indicators. Overall, the strength of the trend is weak, with the Dow Theory indicating a mildly bullish stance on both weekly and monthly time frames.

Who are the top shareholders of the Evoq Remedies?

The top shareholders of Evoq Remedies are primarily individual investors, holding 84.74% of shares. Notably, Dhruv Ganji is the largest public shareholder at 11.35%, while promoter Patel Payal Bhumishth holds 6.02%.

The top shareholders of Evoq Remedies include individual investors who hold a significant portion of the company, accounting for 84.74% of the total shares. Among the major shareholders, the highest public shareholder is Dhruv Ganji, who holds 11.35%. Additionally, Patel Payal Bhumishth is the promoter with the highest holding at 6.02%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

How big is Evoq Remedies?

As of 24th July, Evoq Remedies Ltd has a market capitalization of 10.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 25.24 Cr and Total Assets of 36.86 Cr reported as of March 2024. There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Evoq Remedies Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2024, with Shareholder's Funds amounting to 25.24 Cr and Total Assets valued at 36.86 Cr.

How has been the historical performance of Evoq Remedies?

Evoq Remedies has shown significant financial fluctuations, with net sales increasing to 11.76 Cr in March 2025 from 4.05 Cr in March 2024, but down from 20.39 Cr in March 2023. The company reported a cash flow outflow of -14.00 Cr in March 2025, indicating a volatile financial trajectory.

Answer:<BR>The historical performance of Evoq Remedies shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Evoq Remedies reported net sales of 11.76 Cr in March 2025, a notable increase from 4.05 Cr in March 2024, but a decline from 20.39 Cr in March 2023. The total operating income mirrored this trend, reaching 11.76 Cr in March 2025, up from 4.05 Cr in the previous year, yet down from 20.39 Cr in March 2023. The total expenditure, excluding depreciation, was 13.99 Cr in March 2025, rising from 5.69 Cr in March 2024, while the operating profit (PBDIT) was slightly positive at 0.18 Cr, down from 0.62 Cr in March 2024 and 2.28 Cr in March 2023. The profit before tax decreased to 0.13 Cr in March 2025 from 0.61 Cr in March 2024, and the profit after tax also fell to 0.09 Cr from 0.45 Cr in the previous year. The company's total assets increased to 50.01 Cr in March 2025 from 36.86 Cr in March 2024, while total liabilities rose to 50.01 Cr from 36.86 Cr. The cash flow from operating activities showed a significant outflow of -14.00 Cr in March 2025, contrasting with a positive inflow of 5.00 Cr in March 2024. Overall, Evoq Remedies has experienced a volatile financial trajectory, with varying sales, profits, and cash flows over the years.

When is the next results date for Evoq Remedies?

Evoq Remedies will announce its results on 10 October 2025.

Evoq Remedies will declare its results on 10 October 2025.

Why is Evoq Remedies Ltd falling/rising?

As of 18-Apr, Evoq Remedies Ltd's stock price is rising to 3.57, reflecting a 5.31% increase. This growth is driven by strong recent performance, significant gains over the past month, and outperformance against the benchmark Sensex, despite a decline in investor participation.

As of 18-Apr, Evoq Remedies Ltd's stock price is rising, currently at 3.57, reflecting a change of 0.18 or 5.31% increase. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 5.62% compared to the Sensex's 1.22%. Additionally, the stock has shown significant growth over the past month, with a remarkable increase of 41.67%, while the Sensex only rose by 3.18% during the same period.<BR><BR>The stock has been on a positive trend, with consecutive gains over the last two days, resulting in an overall return of 11.21% in that timeframe. Furthermore, the current price is higher than the 5-day, 20-day, 50-day, and 100-day moving averages, indicating a strong short-term performance, although it remains below the 200-day moving average.<BR><BR>Despite a decline in investor participation, as evidenced by a 39.81% drop in delivery volume compared to the 5-day average, the stock's liquidity remains adequate for trading. Overall, the combination of strong recent performance, significant short-term gains, and outperformance against the benchmark suggests a positive sentiment surrounding Evoq Remedies Ltd, contributing to its rising stock price.

Which are the latest news on Evoq Remedies?